ABBV vs AZN stock comparison
AbbVie vs. Astrazeneca · data as of November 13, 2026
AbbVie (ABBV) has a market value of about $521.5B, Astrazeneca (AZN) about $286.0B. Over their latest twelve months AbbVie had revenue of $66.0B and Astrazeneca $62.4B.
On our five checks Astrazeneca scores higher: 2.8 out of 5 (average) against 1.8 (weak).
By area, the stronger company is Astrazeneca on value; Astrazeneca on future growth; Astrazeneca on track record; Astrazeneca on financial health.
Astrazeneca is cheaper on earnings (P/E 26.1 vs. 50.8).
AbbVie leads on 6 of the compared lines and Astrazeneca on 17.
Side by side
| ABBV | AZN | |
|---|---|---|
| Size and price | ||
| Market cap | $521.5B | $286.0B |
| Share price | $295.03 | $184.45 |
| Score | ||
| Overall score (of 5) | 1.8 | 2.8 |
| Value | 0 | 1 |
| Future growth | 1 | 2 |
| Track record | 2 | 4 |
| Financial health | 2 | 3 |
| Shareholder returns | 4 | 4 |
| Valuation | ||
| P/E (TTM) | 50.8 | 26.1 |
| Forward P/E | 19.1 | 16.5 |
| Price / free cash flow | 27.6 | 46.9 |
| Price / sales | 7.9 | 4.6 |
| EV / EBITDA | 19.8 | 14.7 |
| PEG | — | 1.20 |
| DCF value vs. price | −20% | −38% |
| Business | ||
| Revenue | $66.0B | $62.4B |
| Net income | $10.3B | $11.0B |
| Free cash flow | $18.9B | $6.1B |
| Net margin | 15.7% | 17.7% |
| Gross margin (5-yr avg.) | 68.3% | 76.8% |
| ROIC (5-yr avg.) | 15.3% | 8.4% |
| Growth | ||
| Revenue growth (1 yr) | 8.6% | 8.6% |
| Revenue growth (5 yrs, per year) | 5.9% | 17.2% |
| EPS growth (5 yrs, per year) | -2.8% | 21.8% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$61.5B | -$26.0B |
| Dividend yield | 2.35% | 1.74% |
| Shareholder yield | 2.5% | 1.9% |
| Analysts | ||
| Upside to average target | +6% | +13% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: ABBV TTM to September 30, 2026, AZN TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, AbbVie or Astrazeneca?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Astrazeneca scores 2.8 out of 5 and AbbVie 1.8; the table shows where each one is stronger.
Is AbbVie cheaper than Astrazeneca?
On trailing earnings, Astrazeneca trades at a P/E of 26.1 and AbbVie at 50.8, so Astrazeneca is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, AbbVie or Astrazeneca?
Over five years Astrazeneca grew revenue about 17.2% a year and AbbVie about 5.9% a year.
Which pays a higher dividend?
AbbVie yields 2.35% and Astrazeneca 1.74%.
Full AbbVie analysis → Full Astrazeneca analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.